These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23528598)

  • 1. [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
    Kotov SV; Fedorova SI; Iakushina TI; Lizhdvoĭ VIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):74-8. PubMed ID: 23528598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod for multiple sclerosis: a review for the specialist nurse.
    Harrison K
    Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of fingolimod in clinical practice.
    Thomas K; Ziemssen T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S60-4. PubMed ID: 24321158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod for the treatment of relapsing multiple sclerosis.
    Singer BA
    Expert Rev Neurother; 2013 Jun; 13(6):589-602. PubMed ID: 23738997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
    J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
    Cascione M; Wynn D; Barbato LM; Pestreich L; Schofield L; McCague K
    J Med Econ; 2013 Jul; 16(7):859-65. PubMed ID: 23647445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod in a patient with Wolff-Parkinson-White syndrome.
    Huys AC; Lalive PH; Sekoranja L
    Mult Scler; 2014 Apr; 20(5):636-7. PubMed ID: 23897641
    [No Abstract]   [Full Text] [Related]  

  • 15. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Gábor L
    Ideggyogy Sz; 2014 Mar; 67(3-4):141. PubMed ID: 26118259
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S
    Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report.
    Maciejek Z; Wójcik-Drączkowska H; Wawrzyniak S; Niezgodzińska-Maciejek A
    Neurol Neurochir Pol; 2013; 47(2):145-51. PubMed ID: 23650003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Pfender N; Jelcic I; Linnebank M; Schwarz U; Martin R
    Neurology; 2015 Jun; 84(23):2377-8. PubMed ID: 25957334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.